Literature DB >> 16554966

Mechanisms of angiogenesis in gliomas.

O Kargiotis1, J S Rao, A P Kyritsis.   

Abstract

Gliomas are the most frequent primary tumors of the central nervous system in adults. Glioblastoma multiforme, the most aggressive form of astrocytic tumors, displays a rapid progression that is accompanied by particular poor prognosis of patients. Intense angiogenesis is a distinguishing pathologic characteristic of these tumors and in fact, glioblastomas are of the most highly vascularized malignant tumors. For this reason, research and therapy strategies have focused on understanding the mechanisms leading to the origin of tumor angiogenic blood vessels in order to develop new approaches that effectively block angiogenesis and cause tumor regression. We discuss here some important features of glioma angiogenesis and we present molecules and factors and their possible functions and interactions that play a role in neovascularization. In spite of the great progress that molecular biology has achieved on investigating tumor angiogenesis, many aspects remain obscure and the complexity of the angiogenic process stands for an obstacle in identifying the exact and complete molecular pathways orchestrating new blood vessels formation, which are necessary for the survival and expansion of these tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16554966     DOI: 10.1007/s11060-005-9097-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  172 in total

1.  Expression of functional formyl peptide receptors by human astrocytoma cell lines.

Authors:  Y Le; J Hu; W Gong; W Shen; B Li; N M Dunlop; D O Halverson; D G Blair; J M Wang
Journal:  J Neuroimmunol       Date:  2000-11-01       Impact factor: 3.478

Review 2.  The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling.

Authors:  F S Jones; P L Jones
Journal:  Dev Dyn       Date:  2000-06       Impact factor: 3.780

3.  Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation.

Authors:  M Hermansson; M Nistér; C Betsholtz; C H Heldin; B Westermark; K Funa
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

4.  Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121).

Authors:  G B Whitaker; B J Limberg; J S Rosenbaum
Journal:  J Biol Chem       Date:  2001-05-01       Impact factor: 5.157

Review 5.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

6.  Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors.

Authors:  M Nakada; H Nakamura; E Ikeda; N Fujimoto; J Yamashita; H Sato; M Seiki; Y Okada
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

7.  Interleukin-8 as a macrophage-derived mediator of angiogenesis.

Authors:  A E Koch; P J Polverini; S L Kunkel; L A Harlow; L A DiPietro; V M Elner; S G Elner; R M Strieter
Journal:  Science       Date:  1992-12-11       Impact factor: 47.728

8.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

Review 9.  Invasion as limitation to anti-angiogenic glioma therapy.

Authors:  K Lamszus; P Kunkel; M Westphal
Journal:  Acta Neurochir Suppl       Date:  2003

10.  Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.

Authors:  P A Forsyth; H Wong; T D Laing; N B Rewcastle; D G Morris; H Muzik; K J Leco; R N Johnston; P M Brasher; G Sutherland; D R Edwards
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

View more
  65 in total

1.  An NF-κB p65-cIAP2 link is necessary for mediating resistance to TNF-α induced cell death in gliomas.

Authors:  Xueyan Zhao; Travis Laver; Suk W Hong; George B Twitty; Annelies Devos; Marijke Devos; Etty N Benveniste; Susan E Nozell
Journal:  J Neurooncol       Date:  2011-01-30       Impact factor: 4.130

Review 2.  Glioblastoma niches: from the concept to the phenotypical reality.

Authors:  Davide Schiffer; Marta Mellai; Enrica Bovio; Ilaria Bisogno; Cristina Casalone; Laura Annovazzi
Journal:  Neurol Sci       Date:  2018-05-08       Impact factor: 3.307

Review 3.  Antiangiogenic strategies for treatment of malignant gliomas.

Authors:  Andrew S Chi; Andrew D Norden; Patrick Y Wen
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

4.  Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis.

Authors:  Ran Zhang; Naren L Banik; Swapan K Ray
Journal:  Brain Res       Date:  2008-09-04       Impact factor: 3.252

Review 5.  NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age.

Authors:  G Kenneth Gray; Braden C McFarland; Susan E Nozell; Etty N Benveniste
Journal:  Expert Rev Neurother       Date:  2014-09-29       Impact factor: 4.618

Review 6.  Effects of irradiation on tumor cell survival, invasion and angiogenesis.

Authors:  Odysseas Kargiotis; Aliki Geka; Jasti S Rao; Athanasios P Kyritsis
Journal:  J Neurooncol       Date:  2010-05-07       Impact factor: 4.130

7.  A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib.

Authors:  Alessandra Santangelo; Marzia Rossato; Giuseppe Lombardi; Salvatore Benfatto; Denise Lavezzari; Gian Luca De Salvo; Stefano Indraccolo; Maria Cristina Dechecchi; Paola Prandini; Roberto Gambari; Chiara Scapoli; Gianfranco Di Gennaro; Mario Caccese; Marica Eoli; Roberta Rudà; Alba Ariela Brandes; Toni Ibrahim; Simona Rizzato; Ivan Lolli; Giuseppe Lippi; Massimo Delledonne; Vittorina Zagonel; Giulio Cabrini
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

Review 8.  Safety of bevacizumab in patients with malignant gliomas: a systematic review.

Authors:  G Simonetti; E Trevisan; A Silvani; P Gaviani; A Botturi; E Lamperti; D Beecher; L Bertero; C Bosa; A Salmaggi
Journal:  Neurol Sci       Date:  2013-11-27       Impact factor: 3.307

9.  Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

Authors:  R M Zuniga; R Torcuator; R Jain; J Anderson; T Doyle; S Ellika; L Schultz; T Mikkelsen
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

Review 10.  Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.

Authors:  David A Reardon; Patrick Y Wen; Annick Desjardins; Tracy T Batchelor; James J Vredenburgh
Journal:  Expert Opin Biol Ther       Date:  2008-04       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.